Alchemab's Chief Executive Officer, Jane Osbourn, commented: "As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly's deep expertise in ...

Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...

- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab.

Eli Lil­ly is set to pay up to $415 million in an ALS deal with Alchemab Therapeutics. ... Lantheus dropped its experimental radiopharmaceutical for prostate cancer that it partnered with Lilly on.